MGA logo

Clinical Trials

Sponsor: Alexion Pharmaceuticals // ALXN1210-MG-306

Location(s) & Physician(s)

  • University of Kansas Medical Center // Dr. Mazen Damachkie
  • Washington University School of Medicine // Dr. Muhammad Al-Lozi


Study Coordinator(s)
KUMC: Katie Jennens // kjennens2@kumc.edu
WUSTL: June Smith // smith.june@wustl.edu


Other Helpful Information
Study Website 

Clinical Trials Study Record

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants with Refractory Generalized Myasthenia Gravis (gMG)

The MGA maintains communication with representatives from clinical research studies in efforts to keep the public informed about potential trials MG patients can participate in. Take a look at some of the latest studies in our area below or visit the clinical trials database to discover all the research studies conducted around the world.

A PDF version of the clinical trials list can be accessed here.

Safety & Efficacy Study of Ravulizumab in Adults with Generalized Myasthenia Gravis

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis

Sponsor: UCB Biopharma S.P.R.L. // UCB MG0003


Location(s) & Physician(s)

  • University of Kansas Medical Center // Dr. Mazen Damachkie
  • Washington University School of Medicine // Dr. Muhammad Al-Lozi


Study Coordinator(s):
KUMC: Ali Ciersdorff // aciersdorff@kumc.edu
WUSTL: June Smith // smith.june@wustl.edu


Other Helpful Information:

Study Website

Clinical Trials Study Record

​Snapshot


The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (gMG). This is a randomized, control trial in which the patient will receive either the investigational drug or placebo through subcutaneous infusion. Eligibility and inclusion criteria can be found in the clinical trial study record. If interested in this study, please contact the appropriate study coordinator based on location and physician of interest.​





Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis

​Snapshot


The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). All investigative site personnel, sponsor staff, sponsor designees, staff directly associated with the conduct of the study, and all participants will be blinded to treatment assignments. This is a randomized, control trial in which the patient will receive either the investigational drug or placebo drug through an IV infusion. After the 26-week randomized-controlled period, participants will enter the open-label extension period of the study and receive ravulizumab. Eligibility and inclusion criteria can be found in the clinical trial study record. If interested in this study, contact the appropriate study coordinator based on location and physician of interest.


Sponsor: Alexion Pharmaceuticals // ECU-MG-303

Location(s) & Physician(s)

  • Saint Louis University // Dr. Jafar Kafaie


Study Coordinator(s)
SLU: Jennifer Light // jennifer.light@health.slu.edu


Other Helpful Information
Clinical Trials Study Record

Alexion Pharmaceuticals Contact: clinicaltrials@alexion.com

​Snapshot


The RAISE study is a multicenter, randomized, double-blind, placebo-controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized myasthenia gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks. Eligibility and inclusion criteria can be found in the clinical trial study record. If interested in this study, please contact the appropriate study coordinator based on location and physician.




​Snapshot


The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity. The study will consist of an up to 4-week Screening Period, 26-week Primary Evaluation Treatment Period, an additional (up to) to 208-week Extension Period, and an 8-week Safety Follow-up Period. Eculizumab will be administered through an intravenous (IV) infusion. Eligibility and inclusion criteria can be found in the clinical trial study record. If interested in this study, please contact the appropriate study coordinator based on location and physician.

Sponsor: Ra Pharmaceuticals // RA101495-02.301


Location(s) & Physician(s)

  • University of Kansas Medical Center // Dr. Constantine Farmakidis


Study Coordinator(s):
KUMC: Samantha Colgan // scolgan@kumc.edu


Other Helpful Information:

Clinical Trials Study Record

Ra Pharmaceuticals Contact: trials@rapharma.com

MGA on Facebook
MGA on Instagram
MGA on Twitter